Analyzing bioAffinity Technologies (BIAF) and Its Rivals

bioAffinity Technologies (NASDAQ:BIAF) is one of 73 publicly-traded companies in the “Diagnostics & Research” industry, but how does it weigh in compared to its competitors? We will compare bioAffinity Technologies to similar businesses based on the strength of its dividends, analyst recommendations, risk, profitability, earnings, valuation and institutional ownership.

Volatility and Risk

bioAffinity Technologies has a beta of 3.93, meaning that its stock price is 293% more volatile than the S&P 500. Comparatively, bioAffinity Technologies’ competitors have a beta of 0.87, meaning that their average stock price is 13% less volatile than the S&P 500.

Insider & Institutional Ownership

1.6% of bioAffinity Technologies shares are owned by institutional investors. Comparatively, 32.6% of shares of all “Diagnostics & Research” companies are owned by institutional investors. 44.3% of bioAffinity Technologies shares are owned by company insiders. Comparatively, 27.1% of shares of all “Diagnostics & Research” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Analyst Recommendations

This is a summary of current recommendations for bioAffinity Technologies and its competitors, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
bioAffinity Technologies	0	0	0	0	N/A
bioAffinity Technologies Competitors	67	246	528	3	2.55

As a group, “Diagnostics & Research” companies have a potential upside of 61.98%. Given bioAffinity Technologies’ competitors higher probable upside, analysts plainly believe bioAffinity Technologies has less favorable growth aspects than its competitors.

Profitability

This table compares bioAffinity Technologies and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
bioAffinity Technologies	-313.34%	-107.20%	-84.10%
bioAffinity Technologies Competitors	-472.30%	-752.61%	-25.14%

Valuation & Earnings

This table compares bioAffinity Technologies and its competitors gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
bioAffinity Technologies	$2.53 million	-$7.94 million	-2.62
bioAffinity Technologies Competitors	$648.65 million	-$35.23 million	-78.09

bioAffinity Technologies’ competitors have higher revenue, but lower earnings than bioAffinity Technologies. bioAffinity Technologies is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Summary

bioAffinity Technologies beats its competitors on 6 of the 10 factors compared.

About bioAffinity Technologies

bioAffinity Technologies, Inc., a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer. It also researches targeted therapies to treat lung cancer and other diseases of the lung at the cellular level. The company was incorporated in 2014 and is based in San Antonio, Texas.